Mark Jason Heath Ellison Net Worth & Insider Trades

Mark Jason Heath Ellison - Chief Development Officer, Opiant Pharmaceuticals, Inc

As of March 3, 2023

What is Mark Jason Heath Ellison's Net Worth?

The current estimated net worth of Opiant Pharmaceuticals, Inc's Chief Development Officer, Mark Jason Heath Ellison, is estimated to be about $258.21K . Mark Jason Heath Ellison owns about 18,751 units of Opiant Pharmaceuticals, Inc common stock. In the last 4 years at Opiant Pharmaceuticals, Inc, Mark Jason Heath Ellison has sold an estimated value of $966.94K worth.

What is Mark Jason Heath Ellison's Past Insider Trading?

Mark Jason Heath Ellison's largest sale order was 1,806 units , worth over $36.48K on January 5, 2023. In total, Mark Jason Heath Ellison has made about 9 transactions over 4 years of their time at Opiant Pharmaceuticals, Inc. Mark Jason Heath Ellison usually trades in January, with the busiest year in 2023. The most recent transaction was a sale order of 610 units , worth over $12.36K on January 31, 2023.

Mark Jason Heath Ellison

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

What is Mark Jason Heath Ellison's' Mailing Address?

  • Mailing address is C/o Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd., Suite 500 Santa Monica CA 90401 CA

What are Opiant Pharmaceuticals, Inc's Past Insider Trades?

Opiant Pharmaceuticals, Inc's most recent insider trade came on January 31, 2023 by Roger Crystal who sold 1,358 units worth $27.51K . In the last 6 years, insiders at Opiant Pharmaceuticals, Inc have sold an estimated value of $23.01M and bought an estimated value of $11.56M worth of shares. Insider trading is most common in January, with the busiest year in 2022. The most active traders at the company are Phil Skolnick, Chief Scientific Officer,  David D. O'Toole, Chief Financial Officer,  and Roger Crystal, Chief Executive Officer .

OPIANT PHARMACEUTICALS, INC. Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...